Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289[1].
in vivo
In the H292 xenograft tumor model, the minimally effective doses of Laprituximab (J2898A) is 3 mg/kg[1].
References
[1] Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8_Supplement): 5467-5467.
